Stoke Therapeutics Adds Veteran Leader to Board, R&D Oversight

Stoke Therapeutics ( (STOK) ) has provided an update.

On April 3, 2026, Stoke Therapeutics’ board expanded to ten members and appointed veteran drug development and regulatory executive Clare Kahn, Ph.D., as an independent Class I director, with her term running until the 2026 annual shareholder meeting. Effective immediately, she also joined the board’s Nominating and Corporate Governance Committee and became chair of the Research and Development Committee, receiving standard director compensation including an annual cash retainer and a stock option grant.

Kahn brings more than 30 years of experience at companies including X-VAX Technology, Pfizer and GlaxoSmithKline, as well as current board service at Solid Biosciences, which Stoke expects to leverage as it advances its Phase 3 program for zorevunersen in Dravet syndrome. The appointment strengthens Stoke’s governance and R&D oversight at a pivotal stage for its lead RNA-based therapy, potentially supporting regulatory strategy and execution as the company seeks to deliver a first disease-modifying treatment in a high-need rare epilepsy market.

The most recent analyst rating on (STOK) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Stoke Therapeutics stock, see the STOK Stock Forecast page.

Spark’s Take on STOK Stock

According to Spark, TipRanks’ AI Analyst, STOK is a Neutral.

The score is driven primarily by solid capitalization and improved 2025 cash flow, partially offset by continued net losses and inconsistent profitability metrics. Technical signals are neutral overall, valuation is constrained by negative earnings, and recent corporate updates are broadly positive due to accelerated Phase 3 timelines and perceived operational momentum.

To see Spark’s full report on STOK stock, click here.

More about Stoke Therapeutics

Stoke Therapeutics, Inc. is a Bedford, Mass.-based biotechnology company focused on restoring protein expression using RNA medicines, leveraging its proprietary TANGO antisense oligonucleotide platform to address haploinsufficiency disorders of the central nervous system and eye. Its lead investigational therapy, zorevunersen, is in Phase 3 development as a potential first-in-class, disease-modifying treatment for Dravet syndrome under a strategic collaboration with Biogen, with Stoke retaining North American rights and Biogen holding commercialization rights in the rest of the world.

The company targets severe genetic diseases such as Dravet syndrome, for which no disease-modifying therapies are currently approved and where unmet medical need is high across an estimated 38,000 patients in the U.S., UK, EU-4 and Japan. Zorevunersen has orphan drug, rare pediatric disease and Breakthrough Therapy designations from U.S. and European regulators, underscoring Stoke’s positioning in the rare epilepsy and broader genetic neurology markets.

Average Trading Volume: 788,723

Technical Sentiment Signal: Buy

Current Market Cap: $1.94B

See more data about STOK stock on TipRanks’ Stock Analysis page.